- Home
- » Tags
- » Apalutamide
Top View
- The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands
- Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide With
- E-Learning: Management of Hormone-Sensitive Prostate Cancer
- 2021 Aetna Standard Plan
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- The Importance of Antiandrogen in Prostate Cancer Treatment
- (Nubeqa™), Apalutamide (Erleada™), Enzalutamide (Xtandi®), Abiraterone (Zytiga®, Yonsa®) EOCCO POLICY
- Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
- A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
- CHMP Assessment Report
- Appendix a - Product Name Index
- A View Into Upcoming Specialty & Traditional Drugs
- Efficacy and Safety Exposure-Response Relationships of Apalutamide In
- CHMP Agenda of the 25-29 January 2021 Meeting
- Erleada 60 Mg Film-Coated Tablets
- Inhibition and Induction of CYP Enzymes in Humans: an Update
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Apalutamide) an Overview of Erleada and Why It Is Authorised in the EU
- Apalutamide, Enzalutamide, and Darolutamide for Non-Metastatic
- PA Drug Name Generic Name PA Summary Name Epaned Enalapril
- Resistant Prostate Cancer
- Cross-Resistance Among Next Generation Anti-Androgen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
- ERLEADA (Apalutamide) RATIONALE for INCLUSION in PA PROGRAM
- Androgen Hazards with COVID-19
- Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer Jinge Zhao1, Shu Ning1, Wei Lou1, Joy C
- Background and Importance Apalutamide, Enzalutamide And
- Erleada® Common Name: Apalutamide PDL Category: Antineoplastics
- A Review of Prostate Cancer Treatment Impact on the CNS and Cognitive Function
- Intravaginal DHEA